Literature DB >> 8430519

Human immunodeficiency virus vaccines.

D P Bolognesi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8430519     DOI： 10.1016/s0065-3527(08)60084-6

Source DB:  PubMed          Journal:  Adv Virus Res        ISSN： 0065-3527            Impact factor:   9.937


× No keyword cloud information.
  4 in total

1.  Conditional reduction of human immunodeficiency virus type 1 replication by a gain-of-herpes simplex virus 1 thymidine kinase function.

Authors:  S M Smith; R B Markham; K T Jeang
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

2.  Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages.

Authors:  N Yahi; J Fantini; K Mabrouk; C Tamalet; P de Micco; J van Rietschoten; H Rochat; J M Sabatier
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

3.  SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.

Authors:  N Yahi; J Fantini; S Baghdiguian; K Mabrouk; C Tamalet; H Rochat; J Van Rietschoten; J M Sabatier
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

4.  Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line.

Authors:  N Yahi; J M Sabatier; S Baghdiguian; F Gonzalez-Scarano; J Fantini
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.